Astion Pharma (Three Products Worldwide Rights) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Astion Pharma (Three Products Worldwide Rights) General Information

Description

Portfolio of manufacturing rights for three dermatological drugs. The portfolio encompasses worldwide rights for Dermadexin, a topical treatment for seborrheic dermatitis; Pruridexin, a topical cream to treat chronic puritis; and ASF-1096, a treatment for discoid lupus erythematosus.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Primary Office
  • Denmark
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Astion Pharma (Three Products Worldwide Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.

Request a free trial

Astion Pharma (Three Products Worldwide Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.

Request a free trial